Navigation Links
Codexis, Teva in Licensing Agreement Final
Date:1/7/2009

REDWOOD CITY, Calif., Jan. 7 /PRNewswire/ -- Codexis, Inc. today announced a licensing agreement with Teva Pharmaceutical Industries Ltd., to produce an important publicly-undisclosed generic product, using a proprietary Codexis biocatalyst. Teva, the largest generic drug manufacturer in the world, is a leading producer of this generic product. The product is one of the largest- selling generic prescription drugs in the United States.

Under the agreement, Teva would be using the Codexis process for key process steps in the manufacture of this product, assuming technical milestones are met. Codexis develops proprietary custom biocatalysts, and its technology contributes to lower pharmaceutical process development and manufacturing costs. Codexis technology is in use by leading drug companies worldwide. Financial terms were not disclosed.

"Codexis is very pleased to be partnering with Teva, providing high value technology in the extremely cost-competitive generics marketplace," said Alan Shaw, Ph.D., Codexis President and Chief Executive Officer. "Our proven technology reduces the cost of pharmaceutical process development and manufacturing, and provides our partners with a significant competitive advantage as they respond to increasing market demands for lower cost pharmaceuticals."

Codexis, Inc. is a clean technology company. Codexis develops biocatalysts used to create powerful, efficient and cleaner chemistry-based manufacturing processes in the life sciences, bioindustrial and chemical marketplaces. Codexis technology is used by global pharmaceutical companies for cost-effective manufacturing of human therapeutics and in the energy industry to enable next generation non-food biofuels. Future commercial applications include carbon management, water treatment and chemical manufacturing. For more information, visit http://www.codexis.com .

Contact: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, FRB, ssidenfaden@frbir.com, 212-827-3771.


'/>"/>
SOURCE Codexis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis, Arch Announce Expanded Collaboration
2. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
3. ABAXIS Announces Worldwide Animal Health Licensing Agreement for Rapid Test Technology
4. Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria
5. DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
6. VisualSonics and Seno Medical Instruments Sign Exclusive Opto-Accoustic Licensing Agreement for Preclinical Research
7. Debiopharm and Aurigene Sign Licensing Agreement for the Development and Commercialisation of Debio 0617, a Novel Inhibitor of an Undisclosed Oncology Pathway
8. Sigma-Aldrich and the University of Illinois Offer New Boronic Acid Surrogates to Researchers Worldwide Through Licensing Agreement
9. Baxter Announces Licensing Agreement for Innocolls Gentamicin Surgical Implant in the United States
10. CEL-SCI Announces Exclusive Licensing Agreement with Teva for Cancer Drug Multikine
11. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2017)... ... April 27, 2017 , ... This month Quorum Review ... that simplifies research studies, accelerates study startup, and improves participant engagement. Developed by ... the first and only IRB-integrated eConsent solution . , “Our mission at ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... a name change to Fluence Analytics. , Fluence Analytics provides proprietary ... and biopharmaceutical manufacturing processes and R&D applications. The company’s patented technologies improve ...
(Date:4/27/2017)... WASHINGTON , April 27, 2017  Kinexum, a ... science products, today announces the appointment of Thomas ... G. Alexander ("Zan") Fleming, M.D., Kinexum founder, who becomes ... strategic advisor to Kinexum clients. Thomas ... take on the Kinexum mission and lead the firm,s ...
(Date:4/26/2017)... ... April 25, 2017 , ... LABS, Inc. (LABS) announced ... added to its extensive test menu: Nucleic Acid Testing (NAT) for ZIKV; and Enzyme ... only able to offer NAT screening for blood donors under an Investigational New Drug ...
Breaking Biology Technology:
(Date:4/17/2017)... 2017 NXT-ID, Inc. (NASDAQ: NXTD ) ... of its 2016 Annual Report on Form 10-K on Thursday April ... ... in the Investor Relations section of the Company,s website at ... at http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... Research and Markets has announced the addition ... their offering. ... tracking market to grow at a CAGR of 30.37% during the ... 2017-2021, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
Breaking Biology News(10 mins):